AR112529A1 - Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer - Google Patents

Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer

Info

Publication number
AR112529A1
AR112529A1 ARP180102390A AR112529A1 AR 112529 A1 AR112529 A1 AR 112529A1 AR P180102390 A ARP180102390 A AR P180102390A AR 112529 A1 AR112529 A1 AR 112529A1
Authority
AR
Argentina
Prior art keywords
aryl
alkyl
heteroatoms selected
ring
optionally substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Ritesh Bhanudasji Tichkule
Michael Scott Visser
Aleem Fazal
Artiom Cernijenko
Simone Bonazzi
Rohan Eric John Beckwith
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR112529A1 publication Critical patent/AR112529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Así como su utilización para el tratamiento de distintos tipos de cáncer. Reivindicación 1: Un compuesto de la fórmula (1), o una sal, hidrato, solvato, profármaco, estereoisómero o tautómero farmacéuticamente aceptable de los mismos, en donde: X¹ es CR³; ⁻ ⁻ ⁻ ⁻ ⁻ es opcionalmente un doble enlace cuando X¹ es CR³ y R³ está ausente; cada R¹ es independientemente alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, o halógeno, o dos R¹ junto con los átomos de carbono a los que están unidos forman un anillo de heterocicloalquilo de 5 ó 6 miembros, o dos R¹, cuando están en átomos adyacentes, junto con los átomos a los que están unidos forman un anillo de arilo C₆₋₁₀ o un anillo heteroarilo de 5 ó 6 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S; R² es alquilo C₁₋₆, -C(O)alquilo C₁₋₆, -C(O)(CH₂)₀₋₃arilo C₆₋₁₀, -C(O)O(CH₂)₀₋₃arilo C₆₋₁₀, arilo C₆₋₁₀, heteroarilo de 5 ó 6 miembros que comprende 1 a 3 heteroátomos seleccionados de O, N y S, cicloalquilo C₃₋₈, o heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, en donde el alquilo está opcionalmente sustituido con uno o más R⁴; y el arilo, heteroarilo, cicloalquilo y heterocicloalquilo están opcionalmente sustituidos con uno o más R⁵, o R¹ y R², cuando están en átomos adyacentes, junto con los átomos a los que están unidos forman un anillo heterocicloalquilo de 5 ó 6 miembros; R³ es H o R³ está ausente cuando ⁻ ⁻ ⁻ ⁻ ⁻ es un doble enlace; cada R⁴ se selecciona independientemente de -C(O)OR⁶, -C(O)NR⁶R⁶’, -NR⁶C(O)R⁶’, halógeno, -OH, -NH₂, CN, arilo C₆₋₁₀, heteroarilo de 5 ó 6 miembros que comprende de 1 a 4 heteroátomos seleccionados entre O, N y S, cicloalquilo C₃₋₈ y un anillo heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, en donde los grupos arilo, heteroarilo, cicloalquilo y heterocicloalquilo están opcionalmente sustituidos con uno o más R⁷; cada R⁵ se selecciona independientemente entre alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, halógeno, -OH, -NH₂, CN, cicloalquilo C₃₋₇, heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, arilo C₆₋₁₀ y heteroarilo de 5 ó 6 miembros que comprende 1 a 3 heteroátomos seleccionados de O, N y S, o dos R⁵, cuando en átomos adyacentes, junto con los átomos a los que están unidos forman un anillo de arilo C₆₋₁₀ o un anillo heteroarilo de 5 ó 6 miembros que comprende 1 a 3 heteroátomos seleccionados de O, N y S, opcionalmente sustituido con uno o más R¹⁰, o dos R⁵, cuando están en átomos adyacentes, junto con los átomos a los que están unidos forman un anillo cicloalquilo C₅₋₇ o un anillo heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados de O, N y S opcionalmente sustituido con uno o más R¹⁰; R⁶ y R⁶’ son cada uno independientemente H, alquilo C₁₋₆ o arilo C₆₋₁₀; cada R⁷ se selecciona independientemente entre alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, -C(O)R⁸, -(CH₂)₀₋₃C₍O₎OR⁸, -C(O)NR⁸R⁹, -NR⁸C(O)R⁹, -NR⁸C(O)OR⁹, -S(O)ₚNR⁸R⁹, -S(O)ₚR¹², hidroxialquilo C₁₋₆, halógeno, -OH, -O(CH₂)₁₋₃CN, -NH₂, CN, -O(CH₂)₀₋₃arilo C₆₋₁₀, adamantilo, -O(CH₂)₀₋₃-heteroarilo de 5 ó 6 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, arilo C₆₋₁₀, heteroarilo monocíclico o bicíclico de 5 a 10 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, cicloalquilo C₃₋₇ y heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados de O, N y S, en donde el alquilo está opcionalmente sustituido con uno o más R¹¹, y el arilo, heteroarilo y heterocicloalquilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados cada uno independientemente de halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y alcoxi C₁₋₆, o dos R⁷ junto con el átomo de carbono al que están unidos forman a =(O), o dos R⁷, cuando en átomos adyacentes, junto con los átomos a los que están unidos forman un anillo de arilo C₆₋₁₀ o un anillo heteroarilo de 5 ó 6 miembros que comprende 1 a 3 heteroátomos seleccionados de O, N y S, opcionalmente sustituido con uno o más R¹⁰, o dos R⁷ junto con los átomos a los que están unidos forman un anillo de cicloalquilo C₅₋₇ o un anillo de heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, opcionalmente sustituido con uno o más R¹⁰; R⁸ y R⁹ son cada uno independientemente H o alquilo C₁₋₆; cada R¹⁰ se selecciona independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxilo C₁₋₆, hidroxialquilo C₁₋₆, halógeno, -OH, -NH₂, y CN, o dos R¹⁰ junto con el átomo de carbono- al que están unidos forman a =(O); cada R¹¹ se selecciona independientemente de CN, alcoxi C₁₋₆, arilo C₆₋₁₀ y heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S, en donde el arilo y el heterocicloalquilo son opcionalmente sustituidos con uno o más sustituyentes seleccionados cada uno independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, halógeno, -OH, -NH₂ y CN; R¹² es alquilo C₁₋₆, haloalquilo C₁₋₆, arilo C₆₋₁₀ o heterocicloalquilo de 5 a 7 miembros que comprende 1 a 3 heteroátomos seleccionados entre O, N y S; Rˣ es H o D; p es 0, 1 ó 2; n es 0, 1 ó 2; n1 es 1 ó 2, en donde n + n1 £ 3; y q es 0, 1, 2, 3, ó 4.
ARP180102390 2017-08-23 2018-08-22 Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer AR112529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762549225P 2017-08-23 2017-08-23

Publications (1)

Publication Number Publication Date
AR112529A1 true AR112529A1 (es) 2019-11-06

Family

ID=63638171

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102390 AR112529A1 (es) 2017-08-23 2018-08-22 Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer

Country Status (37)

Country Link
US (5) US10414755B2 (es)
EP (2) EP4183782A1 (es)
JP (1) JP7386787B2 (es)
KR (1) KR20200044038A (es)
CN (1) CN111051298B (es)
AR (1) AR112529A1 (es)
AU (3) AU2018319577B2 (es)
BR (1) BR112020003373B1 (es)
CA (1) CA3072694A1 (es)
CL (1) CL2020000427A1 (es)
CO (1) CO2020001860A2 (es)
CR (1) CR20200081A (es)
CU (1) CU20200014A7 (es)
DK (1) DK3672949T5 (es)
DO (1) DOP2020000037A (es)
EA (1) EA202090553A1 (es)
EC (1) ECSP20013248A (es)
ES (1) ES2940448T3 (es)
FI (1) FI3672949T3 (es)
HR (1) HRP20230244T1 (es)
HU (1) HUE061895T2 (es)
IL (1) IL272748B2 (es)
JO (1) JOP20200042A1 (es)
LT (1) LT3672949T (es)
MA (1) MA49952B1 (es)
MX (1) MX2020002060A (es)
PH (1) PH12020500125A1 (es)
PL (1) PL3672949T3 (es)
PT (1) PT3672949T (es)
RS (1) RS64058B9 (es)
SA (1) SA520411325B1 (es)
SG (1) SG11202000490PA (es)
SI (1) SI3672949T1 (es)
TW (1) TWI793151B (es)
UY (1) UY37854A (es)
WO (1) WO2019038717A1 (es)
ZA (1) ZA202000208B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454856A4 (en) * 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
JP2021521192A (ja) * 2018-04-13 2021-08-26 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンドおよび同リガンドを含む二機能性化合物
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR112021011874A2 (pt) * 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
MX2021009763A (es) * 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
KR20210129672A (ko) * 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
JP2022527216A (ja) * 2019-04-12 2022-05-31 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
TW202108571A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114650868A (zh) * 2019-10-30 2022-06-21 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
AU2020387392A1 (en) * 2019-11-19 2022-07-14 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4144728A4 (en) * 2020-04-30 2023-08-23 Shanghaitech University HETEROCYCLIC COMPOUND BASED ON A GLUTARIMIDE SKELETON AND USES THEREOF
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
TW202216684A (zh) * 2020-07-09 2022-05-01 大陸商四川海思科製藥有限公司 用於抑制與降解雄激素受體的化合物、醫藥組合物及其應用
CN116134027A (zh) * 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20240050428A1 (en) * 2020-10-07 2024-02-15 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
PE20231190A1 (es) * 2020-10-16 2023-08-15 Dana Farber Cancer Inst Inc Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
UY39671A (es) * 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
IL307343A (en) 2021-04-06 2023-11-01 Bristol Myers Squibb Co Pyridinyl substituted oxisoisoindoline compounds
WO2022232536A1 (en) * 2021-04-29 2022-11-03 Neomorph, Inc. Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical preparations that modulate IKZF2
AU2022324621A1 (en) 2021-08-06 2024-01-18 Celgene Corporation Compositions and methods for selective degradation of engineered proteins
WO2023016518A1 (zh) * 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183919A1 (en) * 2022-03-25 2023-09-28 Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. Bicyclic heteroaryl-containing compounds as ikzf2 degraders
TW202341988A (zh) * 2022-03-25 2023-11-01 密西根大學董事會 Ｉｋｚｆ２降解劑及其用途
WO2023201012A1 (en) * 2022-04-15 2023-10-19 Regents Of The University Of Michigan Ikzf2 degraders and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
CN117881668A (zh) * 2022-08-10 2024-04-12 标新生物医药科技(上海)有限公司 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用
WO2024059107A1 (en) * 2022-09-14 2024-03-21 President And Fellows Of Harvard College Ikzf2 and ck1-alpha degrading compounds and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US7196170B2 (en) 1992-09-14 2007-03-27 The General Hospital Corporation Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP2070920B8 (en) 1996-07-24 2011-04-27 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels
WO2002044372A2 (en) 2000-12-01 2002-06-06 Parker Hughes Institute Nucleotide and protein sequence of helios 3 and methods of use
EP1396493A4 (en) 2001-04-26 2005-08-03 Ajinomoto Kk HETEROCYCLIC COMPOUNDS
DE60231989D1 (de) 2001-08-06 2009-05-28 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20070161696A1 (en) 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
BRPI0514865A (pt) * 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
AU2005311888A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
DE602005023646D1 (de) 2004-12-10 2010-10-28 Siemens Healthcare Diagnostics Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
MX2008012096A (es) 2006-03-22 2008-12-17 Vertex Pharma Inhibidores de proteina cinasa c-met para el tratamiento de trastornos proliferativos.
US20070269827A1 (en) 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
KR101342035B1 (ko) 2006-06-20 2013-12-16 한국과학기술연구원 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
EP2227558A1 (en) 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
KR100957051B1 (ko) 2007-12-28 2010-05-13 한국과학기술연구원 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법
GB2456390A (en) 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
WO2009117122A2 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
BR112012002331A2 (pt) 2009-08-05 2019-09-24 Versitech Ltd composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
WO2011056505A1 (en) 2009-10-26 2011-05-12 Abbott Laboratories Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer
DK2569446T3 (en) 2010-05-12 2018-10-29 Steven E Schutzer DIAGNOSTIC MARKERS FOR NEUROPsychiatric Disease
US20120149715A1 (en) 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US20130281304A1 (en) 2010-08-13 2013-10-24 Andrew P. Feinberg Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors
EP2630158B1 (en) 2010-10-22 2018-12-12 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
EP2717876B1 (en) 2011-06-06 2018-12-19 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
US9910039B2 (en) 2011-07-01 2018-03-06 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
WO2013037118A1 (zh) 2011-09-16 2013-03-21 上海长海医院 ***癌的生物学标志物、治疗靶点及其用途
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US9481866B2 (en) 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
WO2013098797A2 (en) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
AU2013225721B2 (en) 2012-03-02 2018-06-14 The Regents Of The University Of California Expansion of alloantigen-reactive regulatory T cells
GB201207297D0 (en) 2012-04-26 2012-06-06 Senzagen Ab Analytical methods and arrays for use in the same
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
EP2682750A1 (en) 2012-07-02 2014-01-08 Sotio a.s. In vitro method for the diagnosis and surveillance of cancer
CA2886120A1 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US20160007893A1 (en) 2013-02-06 2016-01-14 Loxbridge Research Llp Systems and methods for early disease detection and real-time disease monitoring
WO2014153069A2 (en) 2013-03-14 2014-09-25 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
SG11201506723XA (en) 2013-03-15 2015-09-29 Veracyte Inc Methods and compositions for classification of samples
WO2014200952A2 (en) 2013-06-10 2014-12-18 Suregene, Llc Genetic markers of antipsychotic response
WO2015035367A1 (en) 2013-09-09 2015-03-12 The Scripps Research Institute Methods and systems for analysis of organ transplantation
WO2015050875A1 (en) 2013-10-01 2015-04-09 The Regents Of The University Of California Endometriosis classifier
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
JP6778114B2 (ja) * 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4112738A1 (en) 2014-12-05 2023-01-04 Foundation Medicine, Inc. Multigene analysis of tumor samples
EP3034620A1 (en) 2014-12-17 2016-06-22 Diaxonhit Compositions and methods for diagnosing thyroid cancer
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
EP3050570A1 (en) 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
WO2016140974A1 (en) 2015-03-01 2016-09-09 Novena Therapeutics Inc. Process for measuring tumor response to an initial oncology treatment
EP3298004B1 (en) 2015-05-22 2021-01-06 Biotheryx Inc. Compounds targeting proteins, compositions, methods, and uses thereof
EP3304076A4 (en) 2015-06-02 2018-12-19 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
US20190192565A1 (en) 2015-06-03 2019-06-27 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
CN108135945A (zh) 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
WO2017042337A1 (en) 2015-09-09 2017-03-16 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft Short-chain fatty acids for use in the treatment of cardiovascular disease
WO2017044979A2 (en) 2015-09-11 2017-03-16 Ventria Bioscience Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
AU2016330967B2 (en) 2015-09-30 2021-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thalidomide analogs and methods of use
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3384013A4 (en) 2015-12-04 2019-07-10 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. T-CELLS SPECIFIC TO ANTIGEN TO INDUCE IMMUNE TOLERANCE
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
PL3660004T3 (pl) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
CN110741004B (zh) 2016-12-23 2023-10-17 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
MX2019008934A (es) 2017-01-26 2019-11-05 Arvinas Operations Inc Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
CN106932576A (zh) 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途

Also Published As

Publication number Publication date
AU2022231670A1 (en) 2022-10-06
US10640489B2 (en) 2020-05-05
HUE061895T2 (hu) 2023-08-28
MA49952B1 (fr) 2023-03-31
RS64058B1 (sr) 2023-04-28
WO2019038717A1 (en) 2019-02-28
CL2020000427A1 (es) 2020-08-28
ZA202000208B (en) 2021-07-28
PT3672949T (pt) 2023-03-16
HRP20230244T1 (hr) 2023-04-14
US10414755B2 (en) 2019-09-17
EP3672949A1 (en) 2020-07-01
RU2020111556A (ru) 2021-09-23
CO2020001860A2 (es) 2020-05-29
CN111051298A (zh) 2020-04-21
UY37854A (es) 2019-03-29
SG11202000490PA (en) 2020-03-30
US11053218B2 (en) 2021-07-06
IL272748B2 (en) 2023-02-01
BR112020003373B1 (pt) 2022-08-09
IL272748B (en) 2022-10-01
PL3672949T3 (pl) 2023-05-08
RS64058B9 (sr) 2023-08-31
EP4183782A1 (en) 2023-05-24
TWI793151B (zh) 2023-02-21
KR20200044038A (ko) 2020-04-28
IL272748A (en) 2020-04-30
SI3672949T1 (sl) 2023-04-28
EA202090553A1 (ru) 2020-06-08
FI3672949T3 (fi) 2023-03-23
CR20200081A (es) 2020-05-14
DOP2020000037A (es) 2020-08-15
SA520411325B1 (ar) 2022-06-13
EP3672949B1 (en) 2022-12-21
MA49952A (fr) 2021-04-28
CU20200014A7 (es) 2020-11-30
AU2020277231A1 (en) 2020-12-24
US20210309638A1 (en) 2021-10-07
JOP20200042A1 (ar) 2020-02-20
ES2940448T3 (es) 2023-05-08
PH12020500125A1 (en) 2020-09-14
RU2020111556A3 (es) 2021-12-17
US20190367483A1 (en) 2019-12-05
JP2020531498A (ja) 2020-11-05
US10647701B2 (en) 2020-05-12
MX2020002060A (es) 2020-07-13
BR112020003373A2 (pt) 2020-08-25
ECSP20013248A (es) 2020-05-29
TW201920143A (zh) 2019-06-01
JP7386787B2 (ja) 2023-11-27
DK3672949T5 (da) 2023-05-01
US20190062309A1 (en) 2019-02-28
CA3072694A1 (en) 2019-02-28
US20190359594A1 (en) 2019-11-28
DK3672949T3 (da) 2023-03-27
AU2018319577B2 (en) 2020-10-15
CN111051298B (zh) 2023-06-27
US20200231569A1 (en) 2020-07-23
LT3672949T (lt) 2023-04-11
AU2018319577A1 (en) 2020-02-06
EP3672949B9 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
AR112529A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer
AR116109A1 (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR111295A1 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
AR115822A1 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleuquina-1
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR103252A1 (es) Compuestos de quinazolina
AR110922A1 (es) Compuestos inhibidores del vih
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR101692A1 (es) Compuestos y métodos para inhibir histonas demetilasas
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR119657A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR102851A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR100328A1 (es) Moduladores pirrolidina de gpr40
AR092347A1 (es) Derivados de azaindol